Denali Therapeutics Inc. DNLI Finance Lease, Principal Payments

Finance Lease, Principal Payments at other companies

BioCryst PharmaceuticalsBCRX

——

Revenue-—

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total equity$926.1M-17.5%

Total assets$1.3B-0.4%

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Market cap$3.93B+54.2%

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Denali Therapeutics Inc.'s finance lease, principal payments?: Denali Therapeutics Inc. (DNLI) reported finance lease, principal payments of $17K in Q1 2026.
How has Denali Therapeutics Inc.'s finance lease, principal payments changed year-over-year?: Denali Therapeutics Inc.'s finance lease, principal payments decreased by 99.6% year-over-year, from $4.36M to $17K.